NDAORALFOR SOLUTION
Approved
Dec 2025
Lifecycle
Launch
Competitive Pressure
0/100
Clinical Trials
4
Data completeness
5/8 — Partial
DAYBUE STIX (trofinetide) by Acadia Pharmaceuticals is cytochrome p450 3a4 inhibitors [moa]. First approved in 2025.
Drug data last refreshed 10h ago · AI intelligence enriched 4d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DAYBUE STIX (trofinetide) is an oral solution approved by the FDA on December 11, 2025, developed by Acadia Pharmaceuticals. It functions as a cytochrome P450 3A4 inhibitor, modulating drug metabolism pathways. The specific indication and patient population require further clinical documentation.
Launch16.3 years to LOE
Early-stage launch phase with 44 linked job openings indicates active team expansion and significant commercial investment by Acadia.
Mechanism of Action
Cytochrome P450 3A4 Inhibitors
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (4)
An Open-Label Study of Trofinetide for the Treatment of Girls Two to Five Years of Age Who Have Rett Syndrome
Started Sep 2021
15 enrolled
Rett Syndrome
Open-Label Extension Study of Trofinetide for Rett Syndrome
Started Nov 2020
77 enrolled
Rett Syndrome
Open-Label Extension Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome
Started Jan 2020
154 enrolled
Rett Syndrome
Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome (LAVENDER™)
Started Nov 2019
187 enrolled
Rett Syndrome
Career Relevance
DAYBUE STIX launch phase generates 44 open positions spanning commercial, medical, and data science functions, reflecting Acadia's aggressive commercialization strategy. Opportunities favor operational managers, data analytics roles, and health systems specialists navigating a product with high adherence challenges and seizure monitoring requirements.
Worked on DAYBUE STIX at Acadia Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.